
LifeVantage Corporation has extended its MindBody GLP-1 System into international markets. The system’s success in the US has been credited with the company’s recent 49% year-over-year increase in revenue during the second quarter of the fiscal year.

LifeVantage Corporation announced it has completed an international study of its MindBody GLP-1 System. The in vitro cell study used Enzyme-Linked Immunosorbent Assay (ELISA) to measure total GLP-1 production and used fluorescent microscopy to visualize outcomes.